Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RESEARCH FRONTIERS INCREFR · Entity 7794 | Director | December 31, 2024 | January 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RESEARCH FRONTIERS INC
Report date December 31, 2024 · Filed January 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2034-12-30 | Direct | 90,000 |
Reported balance
After 2024-12-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-31 · Grant · Acquired 45,000 · Balance 90,000 F1: Grant of 27,950 options contingent on shareholder approval at the 2025 Annual Meeting of Stockholders of additional shares issuable under Research Frontiers' 2019 Equity Incentive Plan. If such shareholder approval is not received, these contingent options will automatically terminate. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of 27,950 options contingent on shareholder approval at the 2025 Annual Meeting of Stockholders of additional shares issuable under Research Frontiers' 2019 Equity Incentive Plan. If such shareholder approval is not received, these contingent options will automatically terminate.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2024 Filed Jan 2, 2025 23:47 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001493152-25-000113 · ownership.xml · derivative · entry 1 Peso Eyal · CIK 0001982254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 45,000 shares Expires 2034-12-30 F1 · shares: Grant of 27,950 options contingent on shareholder approval at the 2025 Annual Meeting of Stockholders of additional shares issuable under Research Frontiers' 2019 Equity Incentive Plan. If such shareholder approval is not received, these contingent options will automatically terminate. Read SEC document |
| December 31, 2023 Filed Jan 5, 2024 21:15 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001493152-24-001408 · ownership.xml · derivative · entry 1 Peso Eyal · CIK 0001982254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-12-30 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.